Introduction: Treatment of multiple myeloma has undergone profound changes in the past years thanks to the increased understanding of the biology of the disease and the new treatment options. New drugs and effective approaches are currently available for the treatment of multiple myeloma, including immunomodulatory agents, proteasome inhibitors and autologous stem cell transplantation. Areas covered: We have described the recent updated criteria to start treatment in multiple myeloma and summarized clinical data from major studies including most recent agents. Particularly, results with pomalidomide, carfilzomib, ixazomib, monoclonal antibodies such as elotuzumab, daratumumab, and checkpoint inhibitors have been reported. Both transplant and non-transplant settings have been covered. Expert commentary: Despite the successful improvement in overall survival and time to relapse, multiple myeloma still remains incurable. Therefore, there is still an unmet need for new treatment strategies with novel mechanisms of action, like monoclonal antibodies, novel immunomodulators, and novel proteasome inhibitors. Implementation of these novel drugs in rationally designed therapies with a good balance of efficacy and safety should be carefully considered in order to improve outcome.

How is patient care for multiple myeloma advancing?

BONELLO, FRANCESCA;BRINGHEN, Sara;BOCCADORO, Mario;LAROCCA, Alessandra
Last
2017

Abstract

Introduction: Treatment of multiple myeloma has undergone profound changes in the past years thanks to the increased understanding of the biology of the disease and the new treatment options. New drugs and effective approaches are currently available for the treatment of multiple myeloma, including immunomodulatory agents, proteasome inhibitors and autologous stem cell transplantation. Areas covered: We have described the recent updated criteria to start treatment in multiple myeloma and summarized clinical data from major studies including most recent agents. Particularly, results with pomalidomide, carfilzomib, ixazomib, monoclonal antibodies such as elotuzumab, daratumumab, and checkpoint inhibitors have been reported. Both transplant and non-transplant settings have been covered. Expert commentary: Despite the successful improvement in overall survival and time to relapse, multiple myeloma still remains incurable. Therefore, there is still an unmet need for new treatment strategies with novel mechanisms of action, like monoclonal antibodies, novel immunomodulators, and novel proteasome inhibitors. Implementation of these novel drugs in rationally designed therapies with a good balance of efficacy and safety should be carefully considered in order to improve outcome.
10
6
551
561
Multiple myeloma; carfilzomib; check point inhibitors; daratumumab; elotuzumab; immunomodulatory agents; ixazomib; monoclonal antibody; panobinostat; pomalidomide; proteasome inhibitors
Genadieva Stavric, Sonja; Bonello, Francesca; Bringhen, Sara; Boccadoro, Mario; Larocca, Alessandra
File in questo prodotto:
File Dimensione Formato  
[Author Vsn] Genadieva Stavric S et al - 2017 - Exp Rev Hematol - How is patient care for MM - Post print.pdf

Accesso aperto

Descrizione: [Restricted access - Author Vsn.] Genadieva Stavric S et al. Expert Rev Hematol . 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19. © 2017 Informa UK Limited, trading as Taylor & Francis Group. The published version is available at: https://www.tandfonline.com/doi/abs/10.1080/17474086.2017.1326814?journalCode=ierr20 | https://doi.org/10.1080/17474086.2017.1326814
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 744.53 kB
Formato Adobe PDF
744.53 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1637667
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 12
social impact